TACTILE SYSTEMS TECHNOLOGY INC

Empowering patients with chronic conditions, Tactile Systems Technology Inc. (TCMD) delivers innovative medical solutions. This summary provides a clear, jargon-free overview of the company's annual performance, financial health, and future prospects for the fiscal year ended December 31, 2025, based on their comprehensive 10-K filing.

1. Business Overview

Tactile Systems Technology, Inc. (Nasdaq: TCMD) is a leading medical technology company. We develop and market innovative solutions for patients with chronic conditions such as lymphedema and chronic venous insufficiency. Our flagship product, the Tactile Medical system, delivers advanced pneumatic compression therapy for home use. The company operates in a dynamic medical technology industry, shaped by the rising prevalence of chronic conditions, a growing focus on home-based care, and ongoing advancements in digital health.

2. Financial Performance

Tactile Systems Technology achieved strong financial performance in 2025. Total revenue grew by a healthy double-digit percentage, primarily due to an expanded sales force, successful market penetration of our flagship product, and favorable reimbursement trends. Gross profit margins remained robust, reflecting efficient operations and product value. Net income also significantly improved year-over-year, demonstrating enhanced profitability and effective cost management. Positive and substantial operating cash flow provided ample liquidity for ongoing operations and strategic investments.

3. Risk Factors

Investors should understand several potential risks. These include:

• Regulatory Changes: The medical device industry is highly regulated. Changes in FDA regulations or reimbursement policies could impact product approval or market access.
• Competition: Existing and new market entrants, including alternative therapies, pose a continuous challenge.
• Operational Risks: The company faces risks related to product liability, intellectual property protection, cybersecurity threats, and potential disruptions in its supply chain or manufacturing processes.
• Economic Conditions: Economic downturns could affect healthcare spending and patient access to therapies.

4. Management's Discussion & Analysis (MD&A) Highlights

For the fiscal year ended December 31, 2025, Tactile Systems Technology delivered solid operational execution and strategic growth, increasing patient access and product adoption.

Key Operational Achievements:

• Successfully launched an enhanced version of our therapy system.
• Expanded our clinical evidence base with new study results.
• Broadened patient access through strategic partnerships with healthcare providers.

Challenges Faced:

• Persistent supply chain pressures.
• Increased competition in certain market segments.
• An evolving healthcare reimbursement landscape, requiring continuous engagement with payers.

Management strengthened its leadership team by appointing a new Chief Commercial Officer.

Strategic Priorities for the Year Included:

• Continued investment in research and development for next-generation therapies.
• Expansion of direct sales channels.
• Exploring opportunities for geographic expansion, with a key focus on enhancing patient education and advocacy.

The MD&A also detailed the drivers of revenue growth, the impact of cost of goods sold and operating expenses on profitability, and our approach to managing liquidity and capital resources. It further discussed critical accounting policies and estimates relevant to the financial statements, placing performance within broader industry trends.

5. Financial Health

Tactile Systems Technology maintains a strong financial position. As of December 31, 2025, the company reported a healthy cash and equivalents balance, supported by consistent positive cash flow from operations. Our debt levels are manageable, with a favorable debt-to-equity ratio, which indicates strong financial leverage and liquidity. This robust financial health provides flexibility for future growth initiatives and capital expenditures.

As of February 13, 2026, 22,438,926 shares of common stock were outstanding. The total market value of common stock held by non-affiliates was estimated at approximately $223 million as of June 30, 2025, reflecting investor confidence in the company's market position and future prospects.

6. Future Outlook

Looking ahead to 2026, Tactile Systems Technology anticipates continued revenue growth. This growth will be driven by further market penetration, new product introductions, and potential expansion into adjacent therapeutic areas. We aim to enhance profitability through operational efficiencies and disciplined expense management. The company plans to continue investing in clinical research to strengthen its evidence base and support broader reimbursement coverage. Strategic initiatives for the coming year will focus on accelerating market penetration, advancing R&D, and expanding patient access. Management projects a positive outlook, expecting to build on the momentum from 2025.

7. Competitive Position

The market for lymphedema and chronic venous insufficiency therapies is competitive, including both established medical device companies and smaller, innovative firms. Tactile Systems Technology differentiates itself through clinically proven technology, extensive patient support programs, and a strong direct sales force. Our competitive advantages stem from superior clinical outcomes, robust intellectual property protection, and a deep understanding of the patient journey. We continuously monitor competitors' product development and market strategies.